Pharmacogenetics: from bench to byte—an update of guidelines

JJ Swen, M Nijenhuis, A de Boer… - Clinical …, 2011 - Wiley Online Library
Currently, there are very few guidelines linking the results of pharmacogenetic tests to
specific therapeutic recommendations. Therefore, the Royal Dutch Association for the …

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants

JK Hicks, JJ Swen, CF Thorn… - Clinical …, 2013 - Wiley Online Library
Polymorphisms in CYP2D6 and CYP2C19 affect the efficacy and safety of tricyclics, with
some drugs being affected by CYP2D6 only, and others by both polymorphic enzymes …

Comparison of the guidelines of the clinical pharmacogenetics implementation consortium and the dutch pharmacogenetics working group

PCD Bank, KE Caudle, JJ Swen… - Clinical …, 2018 - Wiley Online Library
Both the Clinical Pharmacogenetics Implementation Consortium (CPIC) and Dutch
Pharmacogenetics Working Group provide therapeutic recommendations for well‐known …

A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study

JJ Swen, CH van der Wouden, LEN Manson… - The Lancet, 2023 - thelancet.com
Background The benefit of pharmacogenetic testing before starting drug therapy has been
well documented for several single gene–drug combinations. However, the clinical utility of …

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing

…, D Wang, AA Vinks, Y He, JJ Swen… - Clinical …, 2015 - Wiley Online Library
Tacrolimus is the mainstay immunosuppressant drug used after solid organ and
hematopoietic stem cell transplantation. Individuals who express CYP3A5 (extensive and …

[HTML][HTML] Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants …

JK Hicks, K Sangkuhl, JJ Swen… - Clinical …, 2017 - ncbi.nlm.nih.gov
Abstract CYP2D6 and CYP2C19 polymorphisms affect the exposure, efficacy and safety of
tricyclic antidepressants (TCAs), with some drugs being affected by CYP2D6 only (eg …

Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update

…, J Barbarino, JHM Schellens, JJ Swen… - Clinical …, 2018 - Wiley Online Library
The purpose of this guideline is to provide information for the interpretation of clinical
dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the results can be used to …

Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and …

…, K Sangkuhl, M Whirl‐Carrillo, JJ Swen… - Clinical and …, 2020 - Wiley Online Library
Translating CYP 2D6 genotype to metabolizer phenotype is not standardized across clinical
laboratories offering pharmacogenetic (PGx) testing and PGx clinical practice guidelines …

Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing

KE Caudle, CF Thorn, TE Klein, JJ Swen… - Clinical …, 2013 - Wiley Online Library
The fluoropyrimidines are the mainstay chemotherapeutic agents for the treatment of many
types of cancers. Detoxifying metabolism of fluoropyrimidines requires dihydropyrimidine …

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis

…, RHN van Schaik, RHJ Mathijssen, JJ Swen… - The Lancet …, 2018 - thelancet.com
Background Fluoropyrimidine treatment can result in severe toxicity in up to 30% of patients
and is often the result of reduced activity of the key metabolic enzyme dihydropyrimidine …